MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders
Safety Classified by Officially
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension to the use of Casgevy (exagamglogene autotemcel), allowing children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia to receive the gene editing treatment.
The treatment was previously authorised in the UK for patients 12 and over with these serious inherited blood disorders. The latest approval extends its use to younger children who meet the eligibility criteria.
Both severe sickle cell disease and β-thalassemia are genetic conditions caused by errors in the genes for haemoglobin, which is used by red blood cells to carry oxygen around the body.
In people with severe sickle cell disease, this genetic error can lead to attacks of very severe pain, serious and life-threatening infections, and anaemia (whereby your body has difficulty carrying oxygen).
In people with β-thalassaemia, it can lead to severe anaemia. Patients often need a blood transfusion every 3 to 5 weeks, and injections and medicines throughout their lives.
Casgevy works by editing a faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin. The stem cells are collected from the patient, edited in a laboratory and then infused back into the body following conditioning treatment.
Julian Beach, MHRA Executive Director Operations, said:
“Severe sickle cell disease and β-thalassemia are serious, lifelong conditions that in some cases can be fatal.
“This approval means this innovative gene-editing treatment can now be used in eligible children from the age of five, extending this treatment option to younger patients. It is based on careful assessment of the available evidence on the treatment’s safety, quality and effectiveness.
“As with all medicines, we will continue to closely monitor the safety and effectiveness of Casgevy.”
This is an extract. The publication continues at the source.
Contains public sector information licensed under the Open Government Licence v3.0. Licence
Read the original at the source: https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders
Officially imported this from Medicines and Healthcare products Regulatory Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Medicines and Healthcare products Regulatory Agency — imported from official source
- Official source
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency.atom ATOM
- Imported
- October 30, 2026 10:00
- Versions
- 1 recorded
- Identity
-
https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-ag...